Last reviewed · How we verify
NCT05851755: LUCENT
Italian Lung Cancer Observational Study
trial in Lung Cancer in 1,000 participants. Enrolling by invitation.
31 March 2028
Quick facts
| Lead sponsor | The Mediterranean Institute for Transplantation and Advanced Specialized Therapies |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 April 2023 |
| Primary completion | 31 March 2028 |
| Estimated completion | 31 March 2028 |
| Sites | 1 location across Italy |
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
LUCENT is an observational study focused on malignant pulmonary and tracheo-bronchial disease. It involves a large proportion of reference Italian thoracic surgery centers. The relevance of the study is related to the epidemiology of lung cancer in the world - also known as "Big Killer" - and the high mortality rates both in males and females. The aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. These results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT).
Bertolaccini L, Ciani O, Lucchi M, Zaraca F, et al · · 2024 · cited 1× · PMID 39378423 · DOI 10.2196/57183
Verify or expand the search:
- PubMed search for NCT05851755
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other The Mediterranean Institute for Transplantation and Advanced Specialized Therapies trials
Trials by the same sponsor.
- NCT06814639 — The Aims of the Study Are to Translate the Index of Professional Governance (IPG 3.0) Into Italian and Validate It and t · not yet recruiting
- NCT06268106 — Graphic Novel for Patients Undergoing EUS-FNB · NA · unknown
- NCT03815773 — PRospective Multicenter Observational Study on Transfusion Practice in Vv-ECMO Patients: The PROTECMO Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05851755 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
- Last refreshed: 10 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05851755.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing